The efficacy of neoadjuvant immunotherapy combined with chemotherapy in elderly patients with gastric cancer: A subgroup analysis of the <scp>NEOSUMMIT</scp>‐01 study-Reference-Cited by-同舟云学术

The efficacy of neoadjuvant immunotherapy combined with chemotherapy in elderly patients with gastric cancer: A subgroup analysis of the NEOSUMMIT‐01 study

Published:2024-08 Issue:4 Volume:7 Page:453-455
ISSN:2475-0360
Container-title:AGING MEDICINE
language:en
Short-container-title:Aging Medicine

Author:

An Nan¹^ORCID,Nie Run‐cong¹,Wang Feng²³,Yuan Shu‐qiang¹

Affiliation:

1. Department of Gastric Surgery Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou China

2. Department of Medical Oncology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat‐sen University Guangzhou China

3. Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer Chinese Academy of Medical Sciences Guangzhou China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/agm2.12356

Reference7 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot

3. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

4. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

5. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial